Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | PKM | P14618 | 1/20 | 0.57 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.46 |
| ▸ | RORC | P51449 | 3/20 | 0.45 |
| ▸ | NAMPT | P43490 | 4/20 | 0.44 |
| ▸ | GNRHR | P30968 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | TP53 | P04637 | 2/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22358112 | 0.87 | HDAC4 (0.54) | GPR119MEN1KMT2ALMNA | |
| SCHEMBL22358352 | 0.85 | NAMPT (0.47) | KDM4EPKMNAMPT | |
| SCHEMBL20116317 | 0.80 | USP30 (0.44) | GPR119 | |
| SCHEMBL20676379 | 0.79 | GPR119 (0.44) | GPR119KMT2A | |
| SCHEMBL10144835 | 0.79 | KDM4E (0.76) | KDM4EPKMGPR119NAMPTGNRHR | |
| SCHEMBL20676531 | 0.78 | GPR119 (0.51) | GPR119 | |
| SCHEMBL20676369 | 0.78 | GPR119 (0.56) | GPR119NAMPT | |
| SCHEMBL22358260 | 0.77 | GPR119 (0.49) | GPR119LMNA | |
| SCHEMBL20117079 | 0.76 | TLR8 (0.49) | GPR119 | |
| SCHEMBL20676592 | 0.76 | GPR119 (0.50) | GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11873298-B2 | Compounds and uses thereof | JANSSEN PHARMACEUTICA NV (BE) | 2024-01-16 | — | — | US | disclosed |
| US-20200262828-A1 | COMPOUNDS AND USES THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2020-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11873298-B2 | Compounds and uses thereof | NLN, ACHE, CLN6 | KDM4E 2853/4885PKM 1304/4885GPR119 2922/4885 |
| US-20200262828-A1 | COMPOUNDS AND USES THEREOF | NLN, ACHE, CLN6 | KDM4E 2853/4885PKM 1304/4885GPR119 2922/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.